Previous Close | 0.5000 |
Open | 0.5000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expire Date | 2025-01-17 |
Day's Range | 0.5000 - 0.5000 |
Contract Range | N/A |
Volume | |
Open Interest | 30 |
Investors who take an interest in Syros Pharmaceuticals, Inc. ( NASDAQ:SYRS ) should definitely note that the Chief...
Syros Pharmaceuticals Inc (NASDAQ:SYRS) is a biopharmaceutical company focused on the development of treatments for cancer and diseases caused by gene expression dysregulation. On the day of the transaction, shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) were priced at $1.61, valuing the company with a market cap of $42.094 million. Over the past year, Jason Haas has increased his holdings in Syros Pharmaceuticals Inc (NASDAQ:SYRS) by purchasing 100,000 shares, with no recorded sales of shares by the insider.
On the date of the purchase, shares of Syros Pharmaceuticals Inc were priced at $1.61, leading to a market cap of approximately $42.094 million. According to GF Value, the stock is currently significantly overvalued, with a price-to-GF-Value ratio of 2.93.